Labcorp Q3 adjusted EPS $4.18 vs $3.50; raises FY adjusted EPS midpoint to $16.15-$16.50

LABCORP HOLDINGS INC.

2025-Q3 EPS reported $8.48 revenue$10,435,900,000

Revenue $3.56B (+8.6% YoY); diluted EPS $3.12 (vs $2.00); adjusted EPS $4.18 (vs $3.50).
Full-year guidance: revenue growth 7.4%-8.0% (midpoint lowered 40 bps), adjusted EPS $16.15-$16.50 (midpoint +$0.05).
Free cash flow 9M 2025 $715.7M; FY guidance raised to $1.17B-$1.29B.
Acquired oncology assets from BioReference, signed deals with Empire City Labs, Laboratory Alliance, and Crouse Health.
Quarterly dividend $0.72/share payable Dec 11, 2025; repurchased $25M stock in Q3.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.